Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Maria Amaya to Bridged Bicyclo Compounds, Heterocyclic

This is a "connection" page, showing publications Maria Amaya has written about Bridged Bicyclo Compounds, Heterocyclic.

 
Connection Strength
 
 
 
1.355
 
  1. Bewersdorf JP, Kewan T, Lanino L, Wei W, Rudra Gupta T, Stempel JM, Al Ali NH, DeZern AE, Sekeres MA, Uy GL, Urrutia S, Carraway HE, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Shallis RM, Zeidner JF, Savona MR, Hawkins H, Chandhok NS, Logothetis CN, Bidikian A, Getz TM, Roboz GJ, Rolles B, Wang ES, Harris AC, Amaya ML, Ball S, Grenet J, Xie Z, Madanat YF, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski JP, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta MG, Komrokji RS, Zeidan AM. Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database. Blood Cancer J. 2026 Jun 29; 16(1).
    View in: PubMed
    Score: 0.201
  2. Jones MK, Sanchez J, Connor M, Julian K, Rezac R, Marciano K, Tobin J, Bosma G, Abbott D, Anttila K, Sohalski C, Belachew A, McMahon C, Kent A, Amaya M, Angelos MG, Schwartz M, Gutman JA, Pollyea DA. Tolerability and Outcomes With Serial Cycles of 28?Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia. Am J Hematol. 2026 Apr; 101(4):728-735.
    View in: PubMed
    Score: 0.196
  3. Lachowiez CA, Heiblig M, Aspas Requena G, Tavernier-Tardy E, Dai F, Ashango AB, Peters DT, Fang J, Kaempf A, Long N, Eide CA, Kurtz SE, Xie W, Agarwal A, Sahasrabudhe A, McMahon CM, Amaya ML, Meyers G, Gandhi A, Leonard J, Hayes-Lattin B, Maziarz RT, Traer E, Cook RJ, Swords R, Braun TP, Saultz JN, Eckel AM, Loken MR, Zeidner JF, Tyner JW, Pollyea DA. Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study. Blood Cancer Discov. 2025 Sep 03; 6(5):437-449.
    View in: PubMed
    Score: 0.190
  4. Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D'Alessandro A, Sherbenou DW, Pollyea DA, Smith C, Jordan CT. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica. 2025 01 01; 110(1):103-116.
    View in: PubMed
    Score: 0.181
  5. Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Abbott D, Becker MW, DeGregori J, Smith CA, D'Alessandro A, Jordan CT. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. 2020 11 05; 27(5):748-764.e4.
    View in: PubMed
    Score: 0.134
  6. Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020 04; 10(4):536-551.
    View in: PubMed
    Score: 0.128
  7. Watts J, Madarang E, Abbott D, Hart P, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Amaya ML, Kent A, McMahon C, Schwartz M, Sekeres MA, Smith C, Bradley T, Taylor J, Chandhok N, Venugopal S, Jordan C, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman JA, Pollyea DA. Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy. Haematologica. 2026 Sep 01; 111(9):2957-2965.
    View in: PubMed
    Score: 0.049
  8. Sheth AI, Althoff MJ, Tolison H, Engel K, Amaya ML, Krug AE, Young TN, Minhajuddin M, Pei S, Patel SB, Winters A, Miller R, Shelton IT, St-Germain J, Ling T, Jones CL, Raught B, Gillen AE, Ransom M, Staggs S, Smith CA, Pollyea DA, Stevens BM, Jordan CT. Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium. Cancer Discov. 2024 Oct 04; 14(10):1922-1939.
    View in: PubMed
    Score: 0.044
  9. Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625.
    View in: PubMed
    Score: 0.041
  10. Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahon CM, Smith CA, Pollyea DA, Jordan CT. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. Cancer Discov. 2023 09 06; 13(9):2032-2049.
    View in: PubMed
    Score: 0.041
  11. Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 08; 58(8):849-854.
    View in: PubMed
    Score: 0.040
  12. Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 09; 6:e2200030.
    View in: PubMed
    Score: 0.038
  13. Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 12 28; 5(24):5565-5573.
    View in: PubMed
    Score: 0.037
  14. Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax?+?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2021 06; 62(6):1466-1473.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)